DSIP 10mg

Quickstart Highlights

Reference-derived details for DSIP 10mg.

Most‑studied human dose: ~25 nmol/kg (≈21 µg/kg) per injection
Frequency: 1× daily; courses of 1–4 consecutive days were commonly explored
Reconstitution: Use the full 3 mL (max vial capacity) → ~3.33 mg/mL for easy unit counting
Units math: At 3 mL, each 100‑unit insulin syringe unit ≈ 33 µg DSIP
Storage: Lyophilized vials frozen; reconstituted solution refrigerated (details below)

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Literature‑Derived Approach (3 mL = 3.33 mg/mL)

Body Weight	Dosage (per injection)	Units (per injection) (mL)
50 kg	~1,061 µg (1.061 mg)	32 units (0.32 mL)
60 kg	~1,273 µg (1.273 mg)	38 units (0.38 mL)
70 kg	~1,485 µg (1.485 mg)	45 units (0.45 mL)
80 kg	~1,698 µg (1.698 mg)	51 units (0.51 mL)
90 kg	~1,910 µg (1.910 mg)	57 units (0.57 mL)
100 kg	~2,122 µg (2.122 mg)	64 units (0.64 mL)

Target per‑injection dose: ~25 nmol/kg (≈21 µg/kg). Administer once daily for 1–4 days based on study designs. The table below converts body weight to approximate per‑injection dose and syringe units when the 10 mg vial is reconstituted to 3.0 mL.
Notes: Values assume reconstitution to 3.0 mL (10 mg ÷ 3 mL ≈ 3.33 mg/mL). Each 1 unit (on a 100‑unit insulin syringe) = 0.01 mL ≈ 33 µg DSIP. If using a different volume, recalculate proportionally. Literature most often reports slow intravenous administration; routes can vary by study. When injection volumes are small (<10 units), consider 30‑unit or 50‑unit syringes for finer measurement—however, at 3 mL dilution, units per injection are generally ≥10 across common body weights.
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall to minimize foaming; do not shake.
Gently swirl until dissolved. Protect from light.
Refrigerate the reconstituted solution at 2–8 °C. Avoid repeated freeze–thaw.

Supplies Needed

Plan based on the number of injections (1× daily for 1–4 days in many studies). One 10 mg vial reconstituted to 3 mL typically provides ~6 doses at ~1.5 mg each (≈70 kg reference). Adjust for body weight using the table above.

Peptide Vials (10 mg):• 1–4 doses ≈ 1 vial• 5–8 doses ≈ 1–2 vials (≥70 kg likely 2)• 9–12 doses ≈ 2 vials
Insulin Syringes: one per injection (plus spares)
Bacteriostatic Water: 1× 30 mL
Alcohol Swabs: 1 box

Protocol Overview

Concise summary of literature‑based dosing used in clinical investigations.

Primary objective in studies: Modulation of sleep architecture (e.g., total sleep time, awakenings, sleep latency)
Schedule: 1× daily dosing for 1–4 days was commonly studied
Dose Basis: ~25 nmol/kg (≈21 µg/kg) per injection
Reconstitution: Use 3.0 mL for a practical 3.33 mg/mL concentration
Storage: Lyophilized at ≤−20 °C; reconstituted at 2–8 °C; avoid freeze–thaw

Dosing Protocol

How to interpret the literature dose for practical measurement.

Per‑injection dose: ~21 µg/kg (i.e., 0.021 mg/kg)
Frequency: Once daily (morning or pre‑sleep timing explored)
Course length: 1–4 days reported; longer use has limited controlled data
Unit conversion: With 3 mL dilution, 1 unit ≈ 33 µg; multiply dose (µg) ÷ 33 to get units
Example (70 kg): ~1.485 mg → ~0.45 mL → ~45 units

Storage Instructions

General peptide stability practices from laboratory guidance.

Lyophilized: Store at ≤−20 °C in a dry, dark environment; minimize moisture exposure
Reconstituted: Refrigerate at 2–8 °C; aliquot if needed and avoid repeated freeze–thaw cycles
Light & air: Protect from light; limit air exposure for solutions

Important Notes

Practical considerations when translating published dosing to measured volumes.

Use new, sterile syringes and rotate injection sites when applicable to your protocol.
Consistency in timing (daily at the same time) helps with standardized observations in study logs.
Monitor for unexpected reactions and discontinue if adverse effects occur; discuss concerns with a qualified professional.
Document weight, dose (µg/kg), units, time of day, and any observed sleep metrics to compare with published outcomes.

How This Works

DSIP is a nonapeptide (~849 Da) reported to cross the blood–brain and blood–CSF barriers in animal models and has been explored in human sleep studies.

Neurophysiology: Modulation of EEG patterns linked to slow‑wave (delta) sleep has been observed in several studies and reviews.
Hormonal/Stress Axes: Investigations have explored effects on ACTH/cortisol dynamics and interactions with other neuroendocrine pathways.
Routes Studied: Intravenous (slow infusion), intranasal, and (in animals) subcutaneous; human literature most often used IV.

Potential Benefits & Side Effects

Clinical findings vary across trials; some reported improvements in sleep parameters (e.g., total sleep time, awakenings), while others found limited clinical significance. Overall tolerability was generally described as good in short‑term studies.

Reported outcomes include changes in total sleep time, sleep latency, awakenings, and sleep efficiency
Open‑label and small controlled studies suggest possible short‑term benefits; effects may be modest and inconsistent
Short‑term studies reported few adverse effects; rigorous long‑term safety data are limited

Lifestyle Factors

When evaluating sleep‑related outcomes, consistent routines improve interpretability.

Maintain regular sleep/wake times and a dark, quiet sleep environment
Limit stimulants late in the day and manage evening light exposure
Support sleep quality with balanced nutrition, stress management, and regular physical activity (not close to bedtime)

Injection Technique

General subcutaneous technique guidance (if applicable to your protocol); some DSIP studies used intravenous administration.

Clean the vial stopper and skin with an alcohol swab
Use fine‑gauge insulin syringes; inject slowly and rotate sites (abdomen, thigh)
Dispose of sharps safely after each injection

Recommended Source

We recommend Prime Lab Peptides for DSIP (10 mg) with rigorous quality controls and documentation.

Independent purity verification and batch documentation
Transparent quality processes aligned with high laboratory standards
Consistent formulation enabling precise measurement

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

– Acute and delayed effects of DSIP on human sleep (25 nmol/kg IV)

DSIP (10mg Vial) Open source
– DSIP in insomnia (summary of clinical investigations)

Contents